Method for detecting drug-resistant mechanism of gefitinib

Abstract

The invention discloses a method for detecting a drug-resistant mechanism of gefitinib and belongs to the field of medicines. The method comprises the following steps: (1) performing high throughput screening on protein signaling molecules participating in gefitinib drug resistance by adopting iTRAQ quantification (isotope labeling relative or absolute quantification) proteomics technology; (2) screening to obtain differential expression protein signaling molecules of gefitinib sensitive lung cancer cell lines and gefitinib rug-resistant cell lines by adopting western blot (western immunoblotting test) technical identification; and (3) proving expression of the protein signaling molecules discovered by interference by adopting MTT (MTT cytotoxicity assay). The sensitivity of gefitinib can be improved, so that the expression level change of the newly discovered protein signaling molecules is proved to be a drug-resistant mechanism of gefitinib. The method contributes to detecting new protein signaling molecules participating in gefitinib drug resistance, and tolerance-resistant drugs are designed by virtue of the new detected protein signaling molecules.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a method for detecting the drug resistance mechanism of gefenib. Background technique [0002] Lung cancer is the malignant tumor with the highest morbidity and mortality in my country and the world. 80% of lung cancer is non-small cell lung cancer. Gefitinib is an effective drug for the treatment of advanced non-small cell lung cancer. Studies have shown that compared with chemotherapy, gefitinib has the following advantages: oral administration; less toxic and side effects; similar or even better efficacy than chemotherapy. However, patients with advanced non-small cell lung cancer will develop drug resistance after taking gefitinib for 10-12 months, resulting in a decrease in the efficacy of the drug. Although the drug resistance mechanism of gefitinib has been understood to a certain extent, the cause of drug resistance has not been found, especially there is no method f...

AI Technical Summary

Problems solved by technology

However, patients with advanced non-small cell lung cancer will develop drug resistance after taking gefitinib for 10-12 months, resulting in the consequences of reduced drug efficacy for patients

Although the drug resistance mechanism of gefitinib has been understood to a certain extent, the cause of drug resistance has not been found, especially there is no method for detecting drug resistance. The resistance mechanism of gefitinib, thus providing new therapeutic strategies for the development of delaying or overcoming gefitinib resistance

Images